Signal Intensity of Contrast Enhancement according to TE in 3.0T MRI T1 Imaging
Source abstract
Abstract
Normal body tissue or lesion characteristics in T1 images have been evaluated; however, how external parameters effect the change in signal intensity by gadolinium-based contrast agent remains unknown. We investigated how contrast enhancement changed according to echo time (TE) in 3.0T magnetic resonance (MR) T1 imaging and determined the optimal settings for TE in contrast-enhanced T1 imaging. Since there are no guidelines regarding parameters for T1 enhancement when using MR-contrast agents, we analyzed results from varying TEs (between 25 and 7 msec) in both a phantom and clinical study. We obtained the following results: contrast percentage of fat to saline increased from 740.0–1003.6%, response start point increased from 30–90 mmol, max peak signal intensity increased from 1771–2425 a.u., max peak point increased from 2–4 mmol, enhancement percentage of the max peak signal intensity (MPSI) to saline increased from 1671.0–2065.2%, the average of SI on each mol as TE increased from 600.8–996.6 a.u., the average of SI as TE on each molar concentration increased from 378–845 a.u., the AEPSS increased from 44.3–140.3%, and the AEPSC increased from 224.3–647.8%. We confirmed that TE can affect contrast enhancement, and the lowest TE has faster and higher effects on contrast enhancement.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced MRI Techniques and Applications · Lanthanide and Transition Metal Complexes · MRI in cancer diagnosis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Bio-Medical Science, Korea University, 145 Anam-ro Sungbuk-ku, Seoul 02841, Korea
Department of Radiological Science & Physical Medicine, Eulji University, 553 Sanseong-daero Soojung-ku Sungnam-city, Kyunggi-do 13135, Korea
References (11)
Show source-provided references
1. Effect of r1 and r2 relaxivity of gadolinium-based contrast agents on the T1-weighted MR signal at increasing magnetic field strengths10.1002/cmmi.1565 ↗
2. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study)10.3174/ajnr.A3033 ↗
3. Relaxation effects in nuclear magnetic resonance absorption10.1103/PhysRev.73.679 ↗
4. Proton relaxation times in paramagnetic solution10.1063/1.1743771 ↗
5. Tissue characterization with t1, t2, and proton density values: results in 160 patients with brain tumors10.1148/radiology.169.3.3187000 ↗
6. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study)10.3174/ajnr.A4154 ↗
7. Comparison of gadoterate meglumine and gadobutrol in the MRI diagnosis of primary brain tumors: A double-blind randomized controlled intraindividual crossover study (the REMIND study)10.3174/ajnr.A5316 ↗
8. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images10.1212/WNL.45.9.1684 ↗
9. Disseminated tuberculomas in spinal cord and brain demonstrated by MRI with gadolinium-DTPA10.1007/BF00588498 ↗
10. MRI of pancreatic neuroendocrine tumours10.1259/bjr.74.886.740968 ↗
11. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines10.1007/s00330-012-2597-9 ↗